Announcements Trials
Browse Landscape

Phase

Phase 2 53Phase 1 42Phase 1/2 22Phase 3 5Phase NA 4Phase EARLY_PHASE1 1Phase 4 1

Status

Recruiting 8Completed 5Unknown 4Withdrawn 2Terminated 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Breast Neoplasms 592Neoplasms 296Carcinoma, Non-Small-Cell Lung 284Prostatic Neoplasms 266Colorectal Neoplasms 213Multiple Myeloma 181Lung Neoplasms 149Neoplasm Metastasis 139Leukemia, Myeloid, Acute 125Leukemia 120Lymphoma 114Lymphoma, Follicular 113Stomach Neoplasms 105Lymphoma, Non-Hodgkin 102Colonic Neoplasms 98Ovarian Neoplasms 96Rectal Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 94Uterine Cervical Neoplasms 93Head and Neck Neoplasms 92Leukemia, Lymphocytic, Chronic, B-Cell 91Pain 90Carcinoma, Hepatocellular 86Pancreatic Neoplasms 81Melanoma 78Lymphoma, Large B-Cell, Diffuse 77Papillomavirus Infections 68Recurrence 66Squamous Cell Carcinoma of Head and Neck 64Parkinson Disease 4, Autosomal Dominant Lewy Body 62

Interventions

romidepsin 210-propargyl-10-deazaaminopterin 2Vitamin B 12 1Vincristine 1MLN 8237 1Gemcitabine 1Folic Acid 1Doxorubicin 1Cyclophosphamide 1CHOP protocol 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Completed × Lymphoma, T-Cell, Peripheral × Clear all
NCT01796002 2023-01-10

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

The Lymphoma Academic Research Organisation

Phase 3 Completed
421 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03349333 2019-10-01

A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL

Mundipharma (China) Pharmaceutical Co. Ltd

Phase 3 Completed
85 enrolled 26 charts
Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT00646854 2019-03-01

ACT-1

University of Aarhus

Phase 3 Completed
136 enrolled
Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT01482962 2018-07-31

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Takeda

Phase 3 Completed
271 enrolled 25 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT00970385 2009-09-09

LTP

University Hospital, Grenoble

Phase 3 Completed
95 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡